GGrantIndex
← Leaderboards

Cellerant Therapeutics, Inc.

San Carlos, CA

Compare ↔
$11,821,701
Total funding
12
Grants

Funding over time

peak $3.1M · FY200519
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$9,563,301 · 11
DOD$2,258,400 · 1

By mechanism

$2,258,400 · 1
R44$2,045,696 · 1
N43$1,907,027 · 2
N44$1,496,276 · 1
R43$1,201,521 · 3
R42$1,117,159 · 1

Investigators at Cellerant Therapeutics, Inc.

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Largest grants

NON-CLINICAL SAFETY EVALUATION OF MYELOID PROGENITORS$2,258,400
· FY2008 · Department of the Army
IGF::OT::IGF: SBIR PHASE II, TOPIC 326: DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS$1,496,276
N44 · FY2016 · CA
Development of a Process for Generating Human MKP$1,489,036
N01 · FY2013 · CA
Application of Expanded Myeloid Progenitors for Infection (Phase II)$1,039,037
R44 · FY2006 · AI
Application of Expanded Myeloid Progenitors for Infection (Phase II)$1,006,659
R44 · FY2007 · AI
Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation$573,592
R42 · FY2018 · AI
Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation$543,567
R42 · FY2019 · AI
Development of ex vivo Expanded Megakaryocyte Progenitors for Platelet Recovery F$500,000
RC1 · FY2008 · AI
Development of ex vivo Expanded Megakaryocyte Progenitors for Platelet Recovery F$500,000
RC1 · FY2009 · AI
Expansion of HSC for rescue in biodefense applications$411,275
R43 · FY2004 · AI
Expansion of HSC for rescue in biodefense applications$393,363
R43 · FY2005 · AI
Attenuation of Radiation-Induced GI Injury by Cultured Myeloid Progenitors$300,000
R41 · FY2007 · CA
Application of expanded progenitors against infections$296,883
R43 · FY2005 · AI
Attenuation of Radiation-Induced GI Injury by Cultured Myeloid Progenitors$294,835
R41 · FY2008 · CA
Development of IL1RAP antibodies targeting AML CS$223,524
N43 · FY2014 · CA
Novel indication for myeloid progenitor use: Induction of tolerance$200,787
R41 · FY2013 · AI
Development of a Process for Generating Human MKP$194,467
N43 · FY2012 · CA
Validation of novel parallel hematopoietic cell sorter$100,000
R43 · FY2003 · HL